TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Insulin naive~* On OAD treatment for at least 4 months with metformin, a sulphonylurea or a combination~* Body Mass Index (BMI) below or equal to 40.0 kg/m2~* HbA1c (glycosylated haemoglobin): 7.0%-10% (both inclusive)~Exclusion Criteria:~* Proliferative retinopathy~* Recurrent major hypoglycaemia~* Cardial problems~* Uncontrolled hypertension~* Impaired hepatic or renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin detemir (basal insulin) (Type: EXPERIMENTAL): Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen.
- Insulin aspart (prandial insulin) (Type: ACTIVE_COMPARATOR): Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.
- Biphasic insulin aspart 30 (biphasic insulin) (Type: ACTIVE_COMPARATOR): Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Behavioral Intervention To Improve Hypertension Control In Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving continuity of care in the outpatient clinics will be eligible. This will be operationalized as 2 visits in the previous year.~* Adults (= 21 years) with hypertension, on antihypertensive medication for = 1 year, and who have current uncontrolled BP will be enrolled.~Patients with CVD:~* chronic stable angina~* unstable angina~* uncomplicated myocardial infarction~* coronary artery bypass surgery~* percutaneous coronary angioplasty~* atherectomy or stent placement~* chronic stable angina pectoris~* stable Class I or Class II congestive heart failure~* stroke~* peripheral vascular disease~will be entered into the study if the CVD event or diagnosis occurred = 6 months ago.~Exclusion Criteria:~Patients with limited life expectancy (\< 1 year) due to severe co-existing non-CVD disease such as:~* terminal illnesses such as terminal cancer~* CVD \< 6 months ago~* Class III or IV CHF~* severe psychiatric illness such as psychosis~* manic depression~* alcohol abuse (\> 21 drinks/week)~* serious chronic conditions like AIDS~* tuberculosis~* lupus~* and end-stage renal failure~will be excluded.~* Other exclusions include inability to understand English~* Lack of a landline telephone~* Unable to follow the study protocol~* Recent major surgery (\< 3 months)~* Patients who are temporarily in the area and plan to move in \< 1 year or will not be available for follow-up~* Those unable to provide informed consent.~* All patients excluded and reason for exclusion will be recorded.~* Prior to recruitment, each patient will be informed about the study and informed consent obtained.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage-matched intervention (SMI) (Type: EXPERIMENTAL): Stage-matched intervention (SMI)
- Health Education Intervention (HEI) (Type: ACTIVE_COMPARATOR): Health Education Intervention (HEI)
- Usual Care (UC) (Type: NO_INTERVENTION): Usual Care (UC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Randomized, Double Blind Treatment Period:~Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features~* Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy~* Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bony disease~* No prior treatment with cytotoxic chemotherapy~* Asymptomatic or mildly symptomatic from prostate cancer~Exclusion Criteria:~* Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment~* Known or suspected brain metastasis or active leptomeningeal disease~* History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer~Open-Label Treatment Period:~The following inclusion criteria apply to patients receiving enzalutamide or placebo during double-blind treatment.~Eligible patients must meet all inclusion criteria.~* Received randomized double-blind treatment in PREVAIL;~* Open-label day 1 visit is within 6 months after this amendment is approved and becomes effective at the study site;~* Is willing to maintain androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist or has had a bilateral orchiectomy;~The exclusion criteria apply only to patients starting new treatment with enzalutamide after receiving placebo as randomized treatment. Each patient must not meet any of the following criteria:~* Has taken commercially available enzalutamide (Xtandi);~* Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment~* Known or suspected brain metastasis or active leptomeningeal disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative clinical history for measles, mumps, rubella, varicella, and zoster~Exclusion Criteria:~* Received any measles, mumps, rubella, or varicella vaccine, either alone or in any combination at any time prior to the study, or is anticipated to receive any of these vaccines outside of study protocol, either alone or in any combination, during the study~* Received immune globulin, a blood transfusion or blood-derived products (does not include autologous blood/blood products) within 5 months (150 days) prior to any dose of the study vaccines or plans to receive these products while enrolled in this study~* Exposed to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the study vaccination~* Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity, including that resulting from steroid use or other immunosuppressive therapy~* Received 1) systemic immunomodulatory steroids \[greater than the~equivalent of 2 mg/kg total daily dose of prednisone\] within 3 months prior to~entering the study, or 2) any dose of systemic immunomodulatory steroids within~7 days prior to entering study, or 3) is expected to require systemic immunomodulatory steroids through the course of the study~* History of allergy or anaphylactoid reaction to gelatin, sorbitol, neomycin, egg proteins (eggs or egg products), chicken proteins, or any component of the study vaccines~* Received salicylates (eg, aspirin or aspirin-containing products) within 14 days prior to study vaccination~* Diagnosis of an active neurological disorder. Enrollment may be considered~when the disease process has been stabilized~* History of seizure disorder, including single febrile seizure~* Diagnosis of active untreated tuberculosis~* History of thrombocytopenia~* Born to a human immunodeficiency virus (HIV) infected mother

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- MMRV (AMP) (Type: EXPERIMENTAL): Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
- MMRV (2006 process) (Type: ACTIVE_COMPARATOR): Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fosamprenavir in Pts With Hepatic Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infected patients with or without hepatic impairment coinfected with HBV or HCV who started FPV/RTV-based therapy on or after January 1, 2008. The FPV/RTV exposed patients will be stratified into four groups for analysis (see interventions A-D for label/description above), according to their degree of baseline hepatic impairment, which will be defined according to FPV/RTV dose received (and APRI score for interventions A and D). The LPV/RTV intervention group must have started this therapy at approved standard doses on or after January 1, 2008.~Exclusion Criteria:~* Receipt of FPV/RTV or LPV/RTV within the year preceding the baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI (Type: None): Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immune Reconstitution in Tuberculosis Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~HIV negative patients, adult patients \>18 years who has not started anti-TB therapy.~Newly diagnosed pulmonary TB confirmed by microscopy or culture but also sputum-negative clinical TB cases (defined according to the WHO 2006 criteria for sputum smear-negative TB ie. clinical symptoms of TB, chest X-ray findings and response to standard treatment).~Exclusion Criteria:~Patients who have already started treatment with anti-TB drugs for more that 5 days.~HIV-positive patients.~History of anti-TB treatment in the past 2 years.~Local extra-pulmonary TB in the absence of lung manifestations.~Hypercalcaemia (serum calcium \> 3 mmol/L) identified at baseline.~Pregnant and breast feeding women.~Any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate) (Type: ACTIVE_COMPARATOR): Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
- Placebo tablets (Type: PLACEBO_COMPARATOR): Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with type 2 diabetes and treated with oral anti-diabetic drugs (OADs) for at least 3 months~* HbA1c: 7.0-11.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.) in subjects on OAD combination therapy~* Body Mass Index (BMI) less than or equal 40 kg/m2~Exclusion Criteria:~* Subjects treated with insulin within the last three months~* Subjects with any serious medical condition~* Females of child bearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant or not using adequate contraceptive methods~* Subjects using any drug (except for OADs), which in the Investigator's opinion could interfere with the glucose level (e.g. systemic corticosteroids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lira 0.6 + Met (Type: EXPERIMENTAL): Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
- Lira 1.2 + Met (Type: EXPERIMENTAL): Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
- Lira 1.8 + Met (Type: EXPERIMENTAL): Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
- Met Mono (Type: ACTIVE_COMPARATOR): Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
- Met + Glim (Type: ACTIVE_COMPARATOR): Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Androgen Effects in HIV-infected Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female 18 - 55~* BMI less than or equal to 26~* HIV-infected~* Androgen deficient, with free testosterone \< 3 pg/mL~* Stable antiretroviral regimen for 3 months prior to study~* Tubal ligation, hysterectomy, or verbalized understanding of appropriate barrier contraception methods. Subjects will be counseled in appropriate barrier contraception methods and the counseling will be documented.~Exclusion Criteria:~* Use of anabolic agent, including testosterone, GH or other preparations within 3 months of the study.~* Use of megestrol acetate within 3 months of the study~* Use of estrogen or any preparation known to affect bone density or bone turnover.This includes oral contraceptives, depo provera or combined progesterone-estrogen injections, and transdermal contraceptive patches.~* Pregnant or breast-feeding~* Hgb \< 9.0 mg/dL~* Current participation in another research study conducted by this investigator or past participation in the DHEA study funded by the same grant as this protocol.~* Creatinine \> 1.5 mg/dL

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 Transdermal Testosterone (Patch) (Type: ACTIVE_COMPARATOR): 300 micrograms applied twice a week
- 2 Placebo Patch (identical in appearance) (Type: PLACEBO_COMPARATOR): placebo patch (0 micrograms of testosterone)applied twice a week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: biomArkers to differeNtiate bacTerial From vIral iNfEctions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Febrile children:~  * Between 7 days and 3 months old : fever \>38°C for more than 6 hours (late neonatal fever suspected) for which the physician prescribed venipuncture~ * Between 3 months and 36 months old : fever ≥38,5°C for more than 6 hours and less than 7 days for which the physician prescribed venipuncture for suspected severe bacterial infection~* Patient with national health cover~* Consent form signed by at least one parent~Exclusion Criteria:~* Children treated by antibiotherapy within the past 48h~* Children with congenital or acquired immunodeficiency syndrome or long-term immunosuppression treatment~* Vaccinated children within 48h by an inactivated vaccine or within 10 days for the MMR vaccines~* Children with a chronic disease~* undergoing surgery within 7 days before inclusion

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- 7 biomarkers combination (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Nasal Influenza Immunisation in Egg Allergic Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 - 17 years old~* Physician-diagnosis of egg allergy~Exclusion Criteria:~* Contraindicated as acutely unwell or current unstable asthma~* Use of asthma reliever medication in last 72 hours~* Recent administration of a medication containing antihistamine within the last 4 days~* Current oral steroid for asthma exacerbation or course completed within last 2 weeks~* Contraindications to ingredient in LAIV (notwithstanding allergy to egg protein)~* Previous allergic reaction to an influenza vaccine~* Children and adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids.~* Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Egg allergic children (Type: None): Administration of Live attenuated influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin Stabilize Cardiovascular Response to Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists(ASA) grade I and II scheduled for elective surgery~Exclusion Criteria:~* patient refusal.~* patients with serious chronic kidney, liver, lungs, or cardiovascular diseases.~* allergy to any of the study medications.~* patients taking sedation or antihypertensive medications.~* suspected difficult intubation or intubation time more than 22s.~* pregnant or breastfeeding women.~* BMI\>30.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: NO_INTERVENTION): the patients receive routine preoperative preparation without having Pregabalin
- Pregabalin150mg group (Type: EXPERIMENTAL): the patients receive 150mg pregabalin 60 minutes prior to the surgery
- Pregabalin300mg group (Type: EXPERIMENTAL): the patients receive 300mg pregabalin 60 minutes prior to the surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
- Outpatients aged 18 to 75 years old with nonpsychotic major depressive disorder (HAMD score 14 or greater)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete